Updated:
Lab Genomics
Lab Genomics bridges South Korean bio-bank infrastructure and Silicon Valley venture capital to invest in AI-driven precision medicine and drug discovery.
Lab Genomics
Founded by a team with dual roots in Korean healthcare systems and Bay Area life-science investing, Lab Genomics was conceived around a central thesis: that validated clinical datasets from East Asian populations represent an undervalued input for the next generation of diagnostic and therapeutic AI. The firm maintains a physical bio-repository in Seongnam, which functions both as a research platform and a deal-screening mechanism, alongside a commercial office in Foster City that manages US venture allocations. Deployment spans three main asset classes: early-stage venture equity in digital health and computational biology startups, structured data-licensing agreements with pharmaceutical partners, and selective direct investments in genetic-sequencing infrastructure companies in the Asia-Pacific region. The firm's portfolio includes positions in companies building liquid-biopsy platforms and AI models for drug repurposing. Investment stages concentrate on Seed to Series B, with the bio-bank often serving as in-kind capital alongside a cash commitment, securing data access rights and board observation seats in the process. The team operates across the Seongnam and Foster City offices. Lab Genomics maintains collaborative ties with several university-hospital systems in South Korea, which feed the longitudinal genomic and phenotypic datasets that underpin its research platform. The structure does not currently include a disclosed philanthropic arm or an affiliated club-vehicle program. The firm's structural distinction lies in its use of proprietary health data as a currency. Unlike generalist healthcare VCs that evaluate startups from the outside, Lab Genomics can diligence and later accelerate portfolio companies by providing de-identified training data, clinical-validation cohorts, and regulatory-pathway intelligence specific to the Korean and Japanese markets. This data-as-equity approach creates a hard-to-replicate sourcing funnel and a post-investment value-add that functions as a moat in genomics investing.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
South Korea
City
Seongnam
Corporate office
Seongnam, South Korea
Additional offices
Foster City, CA, United States
Sector focus
Frequently asked questions
What is Lab Genomics' investment thesis?
The firm invests in early-stage AI and biotechnology startups whose models benefit from access to labeled, population-specific genomic datasets. Lab Genomics uses its proprietary East Asian bio-bank, maintained in South Korea, to both source and diligence deals that would be difficult for a purely US-based fund to evaluate. The thesis targets a valuation gap between data-rich precision medicine companies and the capital markets' slower recognition of biodata as a durable competitive asset.
How does Lab Genomics source proprietary deal flow?
Sourcing is built around the bio-repository in Seongnam. Academic collaborators at Korean university hospitals refer startups seeking validation cohorts, while the Foster City office converts Bay Area founders who need access to Asian phenotypic data for clinical trials or algorithm training. The firm also scans the commercial sequencing ecosystem in Asia for infrastructure plays that sit upstream of the data-generation curve.
Does Lab Genomics commit capital directly or as a fund-of-funds?
Lab Genomics makes direct equity investments and also structures data-licensing arrangements where the bio-bank is contributed as in-kind value. The firm has not publicly disclosed any fund-of-funds commitments, operating instead as a direct investor at the Seed through Series B stages in biotechnology and digital health.
Which sectors does Lab Genomics explicitly avoid?
The firm does not invest in therapeutics companies that require expensive, multi-year FDA clinical trials outside its data partnerships. It also avoids direct-to-consumer genetic testing models with unproven reimbursement pathways. The focus remains on the picks-and-shovels layer of genomic computation rather than long-duration drug development or retail health apps.
Does Lab Genomics maintain philanthropic structures or separate research entities?
No philanthropic foundation or separate research entity has been disclosed. The bio-bank and associated research activities appear to sit within the same corporate structure as the venture operations, though the firm's collaborative agreements with hospital systems include their own institutional review and consent governance.
What is Lab Genomics' known posture on co-investments alongside external GPs?
Lab Genomics participates in syndicated rounds, typically contributing data rights alongside cash from lead investors. The firm will accept a board observation seat rather than a full directorship, integrating its data-platform team into the portfolio company's scientific advisory arrangements. This posture makes Lab Genomics a complementary co-investor for life-science VCs that lack their own Asian genomic datasets.
How is Lab Genomics related to its South Korean hospital partners?
The firm maintains research collaboration agreements with several university-hospital systems in the Seoul metropolitan area, with the bio-bank drawing longitudinal samples and phenotypic data from these institutions under formal data-governance protocols. Lab Genomics is not a subsidiary of or controlled by any single hospital, operating as an independent venture platform that licenses data access in exchange for shared research capabilities.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: